NEW YORK (GenomeWeb News) – UBS today said it has downgraded Bruker BioSciences’ stock to “Neutral" from "Buy."
 
According to Reuters, the brokerage said Bruker’s Daltonics division “faces increasing competition from much larger mass spectrometry vendors, potentially limiting upside.”
 
UBS maintained its $7 price target on Bruker’s stock, Reuters said.
 
The stock was down 1.62 percent, or $.10, at 6.04 in mid-afternoon trading today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.